液体活检在转移性前列腺癌临床管理中的整合。
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.
机构信息
Division of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
出版信息
Curr Oncol Rep. 2022 Oct;24(10):1287-1298. doi: 10.1007/s11912-022-01278-0. Epub 2022 May 16.
Abstract
PURPOSE OF REVIEW
The field of liquid biopsies is constantly evolving through novel technologies. This review outlines current data on liquid biopsies and application to clinical management of metastatic prostate cancer.
RECENT FINDINGS
To date, there are three platforms with FDA approval for use in the setting of metastatic prostate cancer and others which have been clinically validated. There is substantial evidence supporting the use of circulating tumor cell (CTC) enumeration to guide prognosis in metastatic castration-resistant prostate cancer (mCRPC). Additional evidence supports targeted sequencing of CTC and cell-free DNA (cfDNA) to guide androgren-directed therapy, identify candidates for treatment with PARP inhibitors, and monitor development of resistance. As a real-time and minimally invasive approach, utilization of liquid biopsies has the potential to drastically impact the treatment of metastatic prostate cancer and improve overall survival. With further clinical validation, additional liquid biopsy is likely to enter standard clinical practice.
摘要
目的综述
液体活检领域正通过新技术不断发展。本文概述了液体活检的最新数据及其在转移性前列腺癌临床管理中的应用。
最近的发现
迄今为止，有三个获得 FDA 批准用于转移性前列腺癌的平台，还有其他一些已在临床上得到验证。有大量证据支持使用循环肿瘤细胞 (CTC) 计数来指导转移性去势抵抗性前列腺癌 (mCRPC) 的预后。额外的证据支持对 CTC 和无细胞 DNA (cfDNA) 进行靶向测序，以指导雄激素靶向治疗，确定 PARP 抑制剂治疗的候选者，并监测耐药性的发展。作为一种实时和微创的方法，液体活检的应用有可能极大地影响转移性前列腺癌的治疗并改善总体生存率。随着进一步的临床验证，更多的液体活检可能会纳入标准的临床实践。
相似文献
1
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.液体活检在转移性前列腺癌临床管理中的整合。
Curr Oncol Rep. 2022 Oct;24(10):1287-1298. doi: 10.1007/s11912-022-01278-0. Epub 2022 May 16.
2
Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.液体活检在转移性前列腺癌中的发展与应用。
Curr Oncol Rep. 2018 Mar 23;20(4):35. doi: 10.1007/s11912-018-0683-0.
3
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.前列腺癌中循环肿瘤DNA与配对转移组织活检的一致性
J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx118.
4
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.循环肿瘤细胞雄激素受体剪接变体 7 状态在转移性去势抵抗性前列腺癌中的临床效用。
Eur Urol. 2019 Nov;76(5):676-685. doi: 10.1016/j.eururo.2019.04.006. Epub 2019 Apr 27.
5
Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.多基因分析 mCRPC 中的 CTCs 可鉴定出具有临床意义的预后标志物。
Mol Cancer Res. 2018 Apr;16(4):643-654. doi: 10.1158/1541-7786.MCR-17-0539. Epub 2018 Feb 16.
6
AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.外周血循环肿瘤细胞中 AR-V7 的检测：阿比特龙和恩杂鲁胺治疗相关预后的关联
Eur Urol. 2017 Nov;72(5):828-834. doi: 10.1016/j.eururo.2017.07.024. Epub 2017 Aug 14.
7
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.循环肿瘤细胞计数（Epic Sciences）作为转移性去势抵抗性前列腺癌男性患者预后生物标志物的开发和验证。
Eur J Cancer. 2021 Jun;150:83-94. doi: 10.1016/j.ejca.2021.02.042. Epub 2021 Apr 21.
8
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.胚系 DNA 修复缺陷型前列腺癌的治疗结局和杂合性丢失
Eur Urol. 2017 Jul;72(1):34-42. doi: 10.1016/j.eururo.2017.02.023. Epub 2017 Mar 1.
9
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer.当前前列腺癌诊断方法的评估，重点是液体活检和前列腺癌。
Expert Rev Mol Diagn. 2020 Feb;20(2):207-217. doi: 10.1080/14737159.2019.1684265. Epub 2019 Oct 29.
10
Evolution of the Liquid Biopsy in Metastatic Prostate Cancer.液体活检在转移性前列腺癌中的演变。
Urology. 2019 Oct;132:1-9. doi: 10.1016/j.urology.2019.06.006. Epub 2019 Jun 14.
引用本文的文献
1
Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic Frontiers.转移性前列腺癌的精准靶向治疗：治疗前沿的分子见解
Biomolecules. 2025 Apr 27;15(5):625. doi: 10.3390/biom15050625.
2
Prognostic Role of Prostate-specific Antigen Isoforms and Their Early Kinetics in Patients With Metastatic Castration-resistant Prostate Cancer Receiving New Generation Androgen Receptor Targeted Agents.前列腺特异性抗原异构体及其早期动力学在接受新一代雄激素受体靶向药物治疗的转移性去势抵抗性前列腺癌患者中的预后作用
In Vivo. 2025 Mar-Apr;39(2):859-869. doi: 10.21873/invivo.13889.
3
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.循环肿瘤细胞计数与转移性激素敏感型前列腺癌患者的总生存期
JAMA Netw Open. 2024 Oct 1;7(10):e2437871. doi: 10.1001/jamanetworkopen.2024.37871.
4
Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers.通过游离循环生物标志物监测去势抵抗性前列腺癌
Front Oncol. 2024 Sep 10;14:1394292. doi: 10.3389/fonc.2024.1394292. eCollection 2024.
5
Liquid Biopsy in the Clinical Management of Cancers.液体活检在癌症临床管理中的应用。
Int J Mol Sci. 2024 Aug 6;25(16):8594. doi: 10.3390/ijms25168594.
6
Bioprinted research models of urological malignancy.泌尿外科恶性肿瘤的生物打印研究模型
Exploration (Beijing). 2024 Feb 20;4(4):20230126. doi: 10.1002/EXP.20230126. eCollection 2024 Aug.
7
Integrated machine learning algorithms reveal a bone metastasis-related signature of circulating tumor cells in prostate cancer.集成机器学习算法揭示了前列腺癌循环肿瘤细胞中与骨转移相关的特征。
Sci Data. 2024 Jun 27;11(1):701. doi: 10.1038/s41597-024-03551-2.
8
Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.循环肿瘤细胞中 Prostein 表达作为转移性去势抵抗性前列腺癌的预后标志物。
Prostate Cancer Prostatic Dis. 2024 Jun;27(2):339-347. doi: 10.1038/s41391-023-00762-3. Epub 2023 Dec 6.
9
The Role of Cell-Free DNA in Cancer Treatment Decision Making.游离DNA在癌症治疗决策中的作用。
Cancers (Basel). 2022 Dec 12;14(24):6115. doi: 10.3390/cancers14246115.
10
Prognostic significance of lncRNA AP004608.1 in prostate cancer.长链非编码RNA AP004608.1在前列腺癌中的预后意义
Front Oncol. 2022 Sep 29;12:1017635. doi: 10.3389/fonc.2022.1017635. eCollection 2022.
本文引用的文献
1
Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer.转移性前列腺癌中个体 cfDNA 甲基组模式的纵向分析。
Clin Epigenetics. 2021 Aug 28;13(1):168. doi: 10.1186/s13148-021-01155-w.
2
Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.通过靶向多区域测序对异质性局限性前列腺癌进行肿瘤突变的无细胞 DNA 检测。
JCO Precis Oncol. 2021 Apr 27;5. doi: 10.1200/PO.20.00428. eCollection 2021.
3
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.早期循环肿瘤细胞动态变化对评估多西他赛在转移性去势抵抗性前列腺癌（mCRPC）患者中的获益价值
Cancers (Basel). 2021 May 12;13(10):2334. doi: 10.3390/cancers13102334.
4
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.循环肿瘤细胞计数（Epic Sciences）作为转移性去势抵抗性前列腺癌男性患者预后生物标志物的开发和验证。
Eur J Cancer. 2021 Jun;150:83-94. doi: 10.1016/j.ejca.2021.02.042. Epub 2021 Apr 21.
5
Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer.免疫荧光AR-V7循环肿瘤细胞检测方法的开发——一种针对转移性前列腺癌男性患者的血液检测。
J Circ Biomark. 2020 Oct 23;9:13-19. doi: 10.33393/jcb.2020.2163. eCollection 2020 Jan-Dec.
6
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).基线循环肿瘤细胞计数作为转移性去势敏感前列腺癌（SWOG S1216）中 PSA 反应和疾病进展的预后标志物。
Clin Cancer Res. 2021 Apr 1;27(7):1967-1973. doi: 10.1158/1078-0432.CCR-20-3587. Epub 2021 Jan 26.
7
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
8
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.转移性去势抵抗性前列腺癌中循环肿瘤细胞AR-V7及紫杉烷与激素治疗结局的前瞻性多中心研究
JCO Precis Oncol. 2020 Oct 28;4. doi: 10.1200/PO.20.00200. eCollection 2020.
9
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌的生存获益。
N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20.
10
Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer.转移性前列腺癌中商业循环肿瘤DNA检测的评估
JCO Precis Oncol. 2019 Jun 12;3. doi: 10.1200/PO.19.00014. eCollection 2019.
Zotero 插件